Motavizumab Completed Phase 2 Trials for Respiratory Syncytial Virus (RSV) Infection / Premature With Gestational Age <=35 Weeks and <=6 Months of Age / Chronic Lung Disease and <= 24 Months of Age or Prevention

IndicationsStatusPurposePhase
CompletedPrevention2
clinicaltrials.gov IdentifierTitleDrugs
NCT00316264Study of Motavizumab (MEDI-524) and Palivizumab Administered Sequentially in the Same Respiratory Syncytial Virus (RSV) Season